Veru (VERU)
Market Price (4/23/2026): $2.44 | Market Cap: $49.6 MilSector: Health Care | Industry: Biotechnology
Veru (VERU)
Market Price (4/23/2026): $2.44Market Cap: $49.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -65% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -121%, 3Y Excs Rtn is -148% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.12 | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -30 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -43% High stock price volatilityVol 12M is 871% Short seller report Key risksVERU key risks include [1] substantial doubt about its ability to continue as a going concern due to severe financial constraints, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -65% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -121%, 3Y Excs Rtn is -148% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.12 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -30 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -43% |
| High stock price volatilityVol 12M is 871% |
| Short seller report |
| Key risksVERU key risks include [1] substantial doubt about its ability to continue as a going concern due to severe financial constraints, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Improved Financial Performance Exceeding Analyst Expectations.
Veru reported significantly improved financial results for its fiscal first quarter ended December 31, 2025, with net loss decreasing to $5.3 million, or $0.26 per share, a notable improvement from the $8.9 million, or $0.61 per share, reported in the prior year's first quarter. This performance surpassed analyst estimates of a -$0.48 loss per share by $0.22. Additionally, the company's operating loss was reduced to $5.4 million from $10.2 million, and cash, cash equivalents, and restricted cash substantially increased to $33.0 million as of December 31, 2025, from $15.8 million as of September 30, 2025.
2. Advancement and Regulatory Clarity in the Enobosarm Obesity Program.
The company's progress in its obesity drug development program, particularly with enobosarm, has been a key driver. Veru announced the enrollment of the first patient in its Phase 2b PLATEAU clinical trial in March 2026, evaluating enobosarm in combination with semaglutide for high-quality weight loss in older patients with obesity. This follows positive efficacy and safety results from the completed Phase 2b QUALITY study, which demonstrated that enobosarm preserved lean mass while enhancing fat loss. Furthermore, successful meetings with the FDA in September 2025 provided clear regulatory pathways for enobosarm's development, confirming that incremental weight loss or clinically significant benefits in physical function could support approval, and that a 3 mg dose of enobosarm is acceptable for future development.
Show more
Stock Movement Drivers
Fundamental Drivers
The 14.0% change in VERU stock from 12/31/2025 to 4/22/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.14 | 2.44 | 14.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 15 | 20 | -27.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| VERU | 14.0% | |
| Market (SPY) | -5.4% | 47.7% |
| Sector (XLV) | -5.4% | 17.7% |
Fundamental Drivers
The -35.8% change in VERU stock from 9/30/2025 to 4/22/2026 was primarily driven by a -27.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.80 | 2.44 | -35.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 15 | 20 | -27.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| VERU | -35.8% | |
| Market (SPY) | -2.9% | 48.4% |
| Sector (XLV) | 5.6% | 15.2% |
Fundamental Drivers
The -50.2% change in VERU stock from 3/31/2025 to 4/22/2026 was primarily driven by a -27.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.90 | 2.44 | -50.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 15 | 20 | -27.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| VERU | -50.2% | |
| Market (SPY) | 16.3% | 0.3% |
| Sector (XLV) | 1.6% | 1.0% |
Fundamental Drivers
The -79.0% change in VERU stock from 3/31/2023 to 4/22/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.60 | 2.44 | -79.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28 | 0 | |
| P/S Multiple | 3.4 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 8 | 20 | -60.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/22/2026| Return | Correlation | |
|---|---|---|
| VERU | -79.0% | |
| Market (SPY) | 63.3% | 2.9% |
| Sector (XLV) | 18.4% | 2.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VERU Return | -32% | -10% | -86% | -10% | -67% | 11% | -97% |
| Peers Return | 29% | 33% | 31% | 24% | 13% | -1% | 212% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 88% |
Monthly Win Rates [3] | |||||||
| VERU Win Rate | 25% | 50% | 50% | 33% | 25% | 75% | |
| Peers Win Rate | 55% | 53% | 48% | 48% | 45% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| VERU Max Drawdown | -32% | -26% | -87% | -49% | -94% | -2% | |
| Peers Max Drawdown | -9% | -22% | -20% | -9% | -24% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VKTX, REGN, LLY, PFE, AMGN. See VERU Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/22/2026 (YTD)
How Low Can It Go
| Event | VERU | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.2% | -25.4% |
| % Gain to Breakeven | 3433.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -48.5% | -33.9% |
| % Gain to Breakeven | 94.1% | 51.3% |
| Time to Breakeven | 43 days | 148 days |
| 2018 Correction | ||
| % Loss | -65.5% | -19.8% |
| % Gain to Breakeven | 189.8% | 24.7% |
| Time to Breakeven | 736 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -45.8% | -56.8% |
| % Gain to Breakeven | 84.6% | 131.3% |
| Time to Breakeven | 25 days | 1,480 days |
Compare to VKTX, REGN, LLY, PFE, AMGN
In The Past
Veru's stock fell -97.2% during the 2022 Inflation Shock from a high on 8/17/2022. A -97.2% loss requires a 3433.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Veru (VERU)
AI Analysis | Feedback
Here are 1-2 brief analogies for Veru:
- A specialized biotech, like a mini-Genentech, focused on developing new cancer treatments.
- A bit like a miniature Johnson & Johnson, balancing a niche medical device business (female condoms) with an ambitious oncology drug development pipeline.
AI Analysis | Feedback
- FC2 female condom/internal condom: A commercial product offering dual protection against unintended pregnancy and sexually transmitted infections.
- Enobosarm: An oral selective androgen receptor agonist in Phase III clinical trial for AR+ ER+ HER2- metastatic breast cancer.
- Sabizabulin (for metastatic breast cancer): A drug candidate in Phase IIb clinical trial for AR+ ER+ HER2- metastatic breast cancer.
- Enobosarm + abemaciclib combination therapy: A combination therapy in Phase III clinical trial for AR+ ER+ HER2- metastatic breast cancer.
- Sabizabulin + enobosarm combination therapy: A combination therapy in Phase II clinical trial for metastatic triple negative breast cancer.
- Sabizabulin (for prostate cancer): A drug candidate in Phase II clinical trial for metastatic castration and androgen receptor targeting agent resistant prostate cancer.
- VERU-100: A GnRH antagonist peptide injection in Phase II clinical trial for advanced hormone sensitive prostate cancer.
- Zuclomiphene Citrate: A drug candidate in Phase II clinical trial for treating hot flashes.
- Sabizabulin (for SARS-CoV-2/ARDS): A drug candidate in Phase III clinical trial for SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome.
- New drug formulation for LUTS: A new drug formulation being developed for lower urinary tract symptoms from an enlarged prostate.
AI Analysis | Feedback
Veru (VERU) sells its commercial products, specifically the FC2 female condom/internal condom, primarily to organizational customers. These include:
- Governmental and Intergovernmental Organizations: Ministries of health, government health agencies, and U.N. agencies.
- Nonprofit Organizations: Various nonprofit entities.
- Commercial Partners: Other commercial entities that partner with Veru for distribution or sales.
AI Analysis | Feedback
nullAI Analysis | Feedback
Mitchell S. Steiner, M.D., F.A.C.S. Chairman, President, and Chief Executive Officer
Dr. Steiner has served as President and Chief Executive Officer of Veru Inc. since October 2016 and as Chairman of the Board since March 2018. He was a co-founder of Aspen Park Pharmaceuticals, Inc., where he served as Chief Executive Officer, President, and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, he was a consultant and then the President, Urology at OPKO Health, Inc., with responsibilities for the launch, marketing, sales, and reimbursement of the 4Kscore prostate cancer test. Dr. Steiner also co-founded GTx, Inc., a men's health and oncology public company, serving as its Chief Executive Officer and Vice Chairman of the Board of Directors from 1997 to 2014. He is a Board Certified Urologist and a Fellow of the American College of Surgeons. He received his M.D. from the University of Tennessee.
Michele Greco Chief Financial Officer and Chief Administrative Officer
Ms. Greco holds the positions of Chief Financial Officer and Chief Administrative Officer at Veru Inc. She is also the Principal Accounting Officer.
Harry Fisch, M.D., F.A.C.S. Vice Chairman, Chief Corporate Officer
Dr. Fisch has served as a director of Veru Inc. since October 2016, as Vice Chairman of the Board since March 2018, and as Chief Corporate Officer since January 2018. He co-founded Aspen Park, where he was Chairman of the Board and Chief Scientific Officer from July 2014 to October 2016. Since 1994, Dr. Fisch has been the Chief Executive Officer and President of Millennium Sciences, Inc.
K. Gary Barnette, Ph.D. Chief Scientific Officer
Dr. Barnette is the Chief Scientific Officer of Veru Inc. Before joining Veru, he was Senior Vice President of Scientific and Regulatory Affairs at Camargo Pharmaceutical Services, LLC for six years, overseeing drug development strategies across various therapeutic areas. From 2000 to 2012, Dr. Barnette held several roles at GTx, Inc., including Vice President, Clinical Development Strategy. He previously served as a Clinical Pharmacology and Biopharmaceutics Reviewer at the U.S. FDA. Dr. Barnette earned his Ph.D. in Basic Pharmaceutical Sciences from West Virginia University, School of Pharmacy.
Gary Bird, Ph.D. Executive Vice President, Quality and Regulatory Affairs
Dr. Bird serves as the Executive Vice President of Quality and Regulatory Affairs at Veru Inc.
AI Analysis | Feedback
The key risks to Veru's business revolve primarily around the success of its lead drug candidate, enobosarm, in clinical trials and its financial viability to see these through to commercialization.
-
Clinical Trial Failure and Regulatory Non-Approval for Enobosarm
Veru's future is heavily dependent on the successful completion of late-stage clinical trials for enobosarm, particularly for its new strategic focus on preserving lean muscle mass in patients taking GLP-1 agonists for weight loss. While Phase 2b results for enobosarm have shown a positive safety profile and the ability to preserve lean mass, success in Phase 3 is not guaranteed and could fail to replicate these results or face new challenges. The FDA has provided regulatory pathways, but success remains contingent on "flawless trial execution and future access to capital." A previous instance where an FDA advisory panel voted against the emergency use authorization of Veru's sabizabulin for COVID-19 highlights the inherent regulatory risks in the biopharmaceutical industry.
-
Financial Instability and Need for Future Capital
Veru has reported ongoing net losses and negative cash flow from operations, indicating financial challenges. The company operates with a significant cash burn rate and has a limited cash runway, frequently necessitating dilutive financing rounds to fund its ambitious clinical development programs. While recent public offerings have strengthened its financial position, management acknowledges that continued clinical development will require additional capital. This financial instability poses a significant risk to the company's ability to complete trials and commercialize its drug candidates.
-
Intense Competition in the GLP-1 Obesity Market
Veru has pivoted its primary focus to developing enobosarm as a companion therapy for GLP-1 agonists to prevent lean mass reduction in the booming obesity market. This market, however, is highly competitive, with numerous large pharmaceutical companies and other biotechs vying for market share. A breakthrough from a competitor with a superior or faster-to-market solution could jeopardize Veru's favorable market position and potential for market adoption, especially as existing GLP-1 treatments already offer significant weight loss.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for Veru's main products and services are as follows:
- FC2 female condom/internal condom: The global female condom market was valued at approximately USD 730 million in 2025. Another source states the market was valued at approximately USD 100 million globally in 2023, projected to grow at a CAGR of 5-7% over the next 5-10 years.
- Enobosarm, Sabizabulin, and Enobosarm + abemaciclib combination therapy for AR+ ER+ HER2- metastatic breast cancer: The market size for ER+/HER2- breast cancer in the United States was USD 6.759 billion in 2022, projected to grow during the forecast period (2026-2036). The US market size is expected to be USD 7.4 billion in 2025. The total metastatic HR+/HER2- breast cancer market size across the 7 Major Markets (7MM) was estimated to be nearly USD 9.1 billion in 2022.
- Sabizabulin + enobosarm combination therapy for metastatic triple negative breast cancer: The global metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.65 billion in 2025 and is expected to reach USD 2.35 billion by 2032. Another estimate for the global mTNBC market is USD 1.66 billion in 2025, growing to USD 2.73 billion by 2035. In the 7MM, the market size for triple-negative breast cancer was found to be USD 4.5 billion in 2024, with the United States accounting for approximately 69% of this market.
- Sabizabulin for metastatic castration and androgen receptor targeting agent resistant prostate cancer: The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market size was valued at USD 21.04 billion in 2025, projected to grow to USD 29.08 billion in 2026 and USD 91.85 billion by 2034. The 7MM metastatic castration-resistant prostate cancer markets reached a value of USD 7.2754 billion in 2024.
- VERU-100 for advanced hormone sensitive prostate cancer: The global Hormone Sensitive Advanced Prostate Cancer Treatment Market is estimated to be valued at USD 14.3 billion in 2025 and is projected to reach USD 28.7 billion by 2035. The Hormone-Sensitive Prostate Cancer Market is projected to reach USD 29.61 billion by 2035 globally.
- Zuclomiphene Citrate for hot flashes: The global menopausal hot flashes market size was valued at USD 8.09 billion in 2025. Other estimates for the global menopausal hot flashes treatment market include USD 6.9 billion in 2024, projected to reach USD 11.5 billion by 2035, and USD 8.76 billion in 2024, projected to grow to USD 16.22 billion by 2034.
- Sabizabulin for SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome: The global Acute Respiratory Distress Syndrome (ARDS) market size is expected to grow from USD 980.4 million in 2021 to USD 2.1376 billion by 2030. In 2023, the Acute Respiratory Distress Syndrome market size in the US was approximately USD 1.643 billion. The 7 major severe acute respiratory syndrome coronavirus infection markets have reached a value of USD 23.8 billion in 2024.
- New drug formulation for lower urinary tract symptoms from an enlarged prostate: The global benign prostatic hyperplasia (BPH) treatment market size was valued at USD 13.0 billion in 2025, expected to reach USD 18.9 billion by 2034. Another source estimates the global market size at USD 12.49 billion in 2024, projected to increase to USD 21.46 billion by 2034.
AI Analysis | Feedback
Veru Inc. (VERU) anticipates future revenue growth over the next 2-3 years to be driven by the advancement and potential commercialization of several key drug candidates in its pipeline.
-
Commercialization of Enobosarm in combination with GLP-1 receptor agonists for high-quality weight loss: Veru is strategically focusing on developing Enobosarm to be combined with GLP-1 receptor agonists to prevent muscle loss and augment fat loss in overweight and obese patients. The company initiated a Phase 2b clinical study for this combination in April 2024, with top-line results expected by the end of calendar year 2024. More recently, Veru enrolled the first patient in its Phase 2b PLATEAU clinical trial for the Enobosarm and Semaglutide combination, with interim results anticipated in Q1 2027.
-
Regulatory approval and commercial launch of Enobosarm for AR+ ER+ HER2- metastatic breast cancer: Enobosarm, an oral selective androgen receptor agonist, is currently in a Phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer.
-
Regulatory approval and commercial launch of Sabizabulin for oncology indications: Sabizabulin, an oral cytoskeleton disruptor, is a lead product candidate in pivotal trials. It is in Phase II clinical trials for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer and metastatic triple-negative breast cancer.
-
Regulatory approval and commercial launch of Sabizabulin for SARS-CoV-2 induced acute respiratory distress syndrome (ARDS): Sabizabulin is also undergoing a Phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome.
AI Analysis | Feedback
Share Repurchases
No information available regarding share repurchases made or authorized by Veru Inc. over the last 3-5 years.
Share Issuance
- Veru Inc. completed an underwritten public offering on October 31, 2025, which included shares of common stock and warrants, generating approximately $23.4 million in net proceeds.
- In December 2023, the company raised approximately $35.2 million through public offerings.
- Shareholders approved an amendment to the 2018 Equity Incentive Plan on March 12, 2026, increasing the number of common shares authorized for issuance for equity awards from 2,600,000 to 5,850,000.
Inbound Investments
No information available regarding large inbound investments made in the company by third-parties over the last 3-5 years, beyond capital raised through public offerings.
Outbound Investments
- Veru Inc. sold its FC2 Female Condom business on December 30, 2024 (fiscal year 2025), for $18 million.
- During fiscal year 2025, the company sold its ENTADFI assets for $20 million, recognizing a gain of $10.8 million.
Capital Expenditures
- Research and development expenses were $15.6 million in fiscal year 2025, an increase from $12.8 million in fiscal 2024, primarily driven by ongoing clinical studies.
- Research and development costs significantly decreased to $1.3 million in the first quarter of fiscal 2026 from $5.7 million in the first quarter of fiscal 2025, due to the wind-down of the Phase 2b QUALITY clinical study.
- Net proceeds from the October 2025 public offering are designated to fund the development of enobosarm, with a primary focus on the Phase 2b PLATEAU clinical study activities.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to VERU.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 190.09 |
| Mkt Cap | 114.7 |
| Rev LTM | 25,547 |
| Op Inc LTM | 6,391 |
| FCF LTM | 4,865 |
| FCF 3Y Avg | 2,366 |
| CFO LTM | 7,468 |
| CFO 3Y Avg | 7,311 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.5% |
| Rev Chg 3Y Avg | 8.8% |
| Rev Chg Q | 5.5% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 20.8% |
| Op Inc Chg 3Y Avg | 17.8% |
| Op Mgn LTM | 26.8% |
| Op Mgn 3Y Avg | 26.9% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 26.4% |
| CFO/Rev 3Y Avg | 24.9% |
| FCF/Rev LTM | 18.3% |
| FCF/Rev 3Y Avg | 19.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 114.7 |
| P/S | 5.2 |
| P/Op Inc | 14.6 |
| P/EBIT | 14.8 |
| P/E | 18.3 |
| P/CFO | 14.2 |
| Total Yield | 4.7% |
| Dividend Yield | 0.6% |
| FCF Yield 3Y Avg | 2.2% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.3% |
| 3M Rtn | 0.6% |
| 6M Rtn | 13.0% |
| 12M Rtn | 27.9% |
| 3Y Rtn | 24.8% |
| 1M Excs Rtn | -7.2% |
| 3M Excs Rtn | -3.3% |
| 6M Excs Rtn | 7.3% |
| 12M Excs Rtn | -8.0% |
| 3Y Excs Rtn | -49.5% |
Price Behavior
| Market Price | $2.44 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/11/1999 | |
| Distance from 52W High | -64.9% | |
| 50 Days | 200 Days | |
| DMA Price | $2.40 | $3.05 |
| DMA Trend | down | down |
| Distance from DMA | 1.5% | -20.0% |
| 3M | 1YR | |
| Volatility | 48.9% | 872.9% |
| Downside Capture | 0.76 | -0.69 |
| Upside Capture | 226.86 | -205.87 |
| Correlation (SPY) | 46.7% | -1.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.36 | 2.06 | 2.09 | 2.48 | 0.13 | 0.97 |
| Up Beta | -1.69 | 0.25 | 0.05 | 1.99 | -0.12 | 0.55 |
| Down Beta | 2.32 | 2.50 | 3.02 | 3.60 | 6.08 | 3.80 |
| Up Capture | 63% | 240% | 279% | 159% | -45% | 26% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 18 | 31 | 59 | 119 | 343 |
| Down Capture | 159% | 199% | 159% | 200% | -98% | 108% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 13 | 23 | 31 | 62 | 126 | 385 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VERU | |
|---|---|---|---|---|
| VERU | -53.5% | 871.1% | 0.83 | - |
| Sector ETF (XLV) | 12.0% | 15.9% | 0.52 | 0.8% |
| Equity (SPY) | 26.7% | 12.5% | 1.77 | -1.3% |
| Gold (GLD) | 38.9% | 27.4% | 1.19 | -4.9% |
| Commodities (DBC) | 23.5% | 16.2% | 1.32 | 1.5% |
| Real Estate (VNQ) | 15.6% | 13.6% | 0.82 | -4.8% |
| Bitcoin (BTCUSD) | -12.8% | 42.6% | -0.21 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VERU | |
|---|---|---|---|---|
| VERU | -43.7% | 409.2% | 0.39 | - |
| Sector ETF (XLV) | 5.6% | 14.6% | 0.20 | 3.1% |
| Equity (SPY) | 10.5% | 17.1% | 0.48 | 4.5% |
| Gold (GLD) | 21.5% | 17.8% | 0.99 | -2.1% |
| Commodities (DBC) | 10.7% | 18.8% | 0.47 | 1.7% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 2.7% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 3.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VERU | |
|---|---|---|---|---|
| VERU | -9.3% | 294.9% | 0.38 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 4.2% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 5.4% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | -1.5% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 2.7% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 3.7% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 2.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/17/2025 | -8.6% | -4.9% | 10.2% |
| 8/12/2025 | -11.7% | -2.2% | 7.5% |
| 5/8/2025 | 4.1% | 0.4% | 23.3% |
| 2/13/2025 | -4.5% | 7.2% | -11.9% |
| 8/8/2024 | 5.3% | 4.0% | 10.3% |
| 5/8/2024 | -12.3% | -9.8% | -43.5% |
| 2/8/2024 | -6.6% | -5.2% | 47.2% |
| 8/10/2023 | 0.9% | 0.0% | -4.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 9 | 10 |
| # Negative | 8 | 9 | 8 |
| Median Positive | 6.4% | 7.2% | 27.3% |
| Median Negative | -9.3% | -4.9% | -10.9% |
| Max Positive | 36.0% | 187.5% | 194.3% |
| Max Negative | -17.4% | -23.5% | -43.5% |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 2/11/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Phase 2b PLATEAU clinical trial initiation | |||||||
| Q1 2027 Phase 2b PLATEAU clinical trial interim analysis | |||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.